Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 12/2005

01-12-2005 | Original Article

Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients

Authors: Ulrike Bacher, Wolfgang Kern, Susanne Schnittger, Wolfgang Hiddemann, Claudia Schoch, Torsten Haferlach

Published in: Annals of Hematology | Issue 12/2005

Login to get access

Abstract

In routine diagnostic procedures of acute myeloid leukemia (AML), the French–American–British (FAB) and World Health Organization (WHO) classifications both play a central role. Some morphologic subtypes are specifically associated to distinct cytogenetic and molecular aberrations; however, such close correlations do not exist for the majority of entities. We evaluated cytogenetics in 2,235 patients at diagnosis of AML with the FAB subtypes M0–2, M4, and M5–7. The cytogenetic patterns of these subtypes showed differences with respect to the clonal aberration rate and the incidence of complex aberrant karyotypes. The frequency of numerical gains and losses and of structural losses and the incidence of 11q23/MLL rearrangements differed. Thus, cytomorphology of AML may be helpful to support or even initiate other diagnostic procedures, e.g., interphase fluorescence in situ hybridization and polymerase chain reaction. In conclusion, the central role of morphology as defined by the FAB and WHO classification in AML at diagnosis is still justified in combination with other techniques.
Literature
1.
Bene MC, Bernier M, Casasnovas RO, Castoldi G, Doekharan D, van der Holt B, Knapp W, Lemez P, Ludwig WD, Matutes E, Orfao A, Schoch C, Sperling C, van’t Veer MB (2001) Acute myeloid leukaemia MO: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 113:737–745CrossRefPubMed
2.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group. Br J Haematol 33:451–458PubMed
3.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia—a report of the French–American–British Cooperative Group. Ann Intern Med 103:620–625PubMed
4.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1991) Proposal for the recognition of minimally differentiated acute myeloid leukemia (Aml-Mo). Br J Haematol 78:325–329PubMed
5.
Bloomfield CD, Herzig GP, Caligiuri MA (1997) Introduction: acute leukemia: recent advances. Semin Oncol 24:1–2PubMed
6.
Cascavilla N, Melillo L, D’arena G, Greco MM, Carella AM, Sajeva MR, Perla G, Matera R, Minervini MM, Carotenuto M (2000) Minimally differentiated acute myeloid leukemia (AML MO): clinico-biological findings of 29 cases. Leuk Lymphoma 37:105–113PubMed
7.
Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doekner H, Tallman MS, Lister TA, LoCocco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642–4649CrossRefPubMed
8.
Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuynck H, Vanorshoven A, Criel A, Stul M, Dalcin P, Hernandez J, Chatelain B, Doyen C, Louwagie A, Castoldi G, Cassiman JJ, Vandenberghe H (1995) Cytogenetic profile of minimally differentiated (Fab M0) acute myeloid leukemia—correlation with clinicobiologic findings. Blood 85:3688–3694PubMed
9.
Cuttner J, Seremetis S, Najfeld V, Dimitriubona A, Winchester RA (1984) Tdt-positive acute leukemia with monocytoid characteristics—clinical, cytochemical, cytogenetic, and immunological findings. Blood 64:237–243PubMed
10.
Dohner K, Tobis K, Ulrich R, Frohling S, Benner A, Schlenk RF, Dohner H (2002) Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the acute myeloid leukemia study group Ulm. J Clin Oncol 20:3254–3261CrossRefPubMed
11.
Roumier C, Eclache V, Imbert M, Davi F, MacIntyre E, Garand R, Talmant P, Lepelley P, Lai JL, Casasnovas O, Maynadie M, Mugneret F, Bilhou-Naberra C, Valensi F, Radford I, Mozziconacci MJ, Arnoulet C, Duchayne E, Dastugue N, Cornillet P, Daliphard S, Garnache F, Boudjerra N, Jouault H, Fenneteau O, Pedron B, Berger R, Flandrin G, Fenaux P, Preudhomme C, Groupe Francais de Cytogenetique Hematologique (GFCH), Groupe Francais d’Hematologie Cellulaire (GFHC) (2005) Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Francais d’Hematologie Cellulaire (GFHC). Leuk Lymphoma 44(11):49–58
12.
Farag SS, Archer KJ, Mrozek K, Vardiman JW, Carroll AJ, Pettenati MJ, Moore JO, Kolitz JE, Mayer RJ, Stone RM, Larson RA, Bloomfield CD (2002) Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol 21:1041–1051PubMed
13.
Grimwade D, Lo Coco F (2002) Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 16:1959–1973CrossRefPubMed
14.
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322–2333PubMed
15.
Gupta V, Minden MD, Yi QL, Brandwein J, Chun K (2003) Prognostic significance of trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemia. Leuk Res 27:983–991CrossRefPubMed
16.
Haferlach T, Bennett JM, Loffler H, Gassmann W, Andersen JW, Tuzuner N, Casslleth PA, Fonatsch C, Schoch C, Schlegelberger B, Becher R, Thiel E, Ludwig WD, Sauerland MC, Heinecke A, Buchner T (1996) Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. Leuk Lymphoma 23:227–234PubMedCrossRef
17.
Haferlach T, Kern W, Schoch C, Hiddemann W, Sauerland MC (2003) Morphologic dysplasia in acute myeloid leukemia: importance of granulocytic dysplasia—reply. J Clin Oncol 21:3004–3005CrossRefPubMed
18.
Haferlach T, Schoch C, Schnittger S, Kern W, Loffler H, Hiddemann W (2002) Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients. Br J Haematol 118:426–431CrossRefPubMed
19.
Haferlach T, Winkemann M, Loffler H, Schoch R, Gassmann W, Fonatsch C, Schoch C, Poetsch M, Weber Matthiesen K, Schlegelberger B (1996) The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May–Grunwald–Giemsa staining and fluorescence in situ hybridization. Blood 87:2459–2463PubMed
20.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849PubMed
21.
Heinonen K, Mrozek K, Lawrence D, Arthur DC, Pettenati MJ, Stamberg J, Qumsiyeh MB, Verma RS, MacCallum J, Schiffer CA, Bloomfield CD (1998) Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study. Br J Haematol 101:513–520CrossRefPubMed
22.
Jaffe E, Lee Harris (2001) Tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
23.
Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T (2004) Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104:3078–3085CrossRefPubMed
24.
Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T (2004) Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica 89:528–540PubMed
25.
Klaus M, Haferlach T, Schnittger S, Kern W, Hiddemann W, Schoch C (2004) Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization. Cancer Genet Cytogenet 155:47–56CrossRefPubMed
26.
Lion T, Haas OA, Harbott J, Bannier E, Ritterbach J, Jankovic M, Fink FM, Stojimirovic A, Herrmann J, Riehm HJ, Lampert F, Ritter J, Koch H, Gadner H (1992) The translocation T(1 22)(P13 Q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood 79:3325–3330PubMed
27.
Loeffler H, Raststetter J, Haferlach T (2005) Atlas of clinical hematology, 6th edn. Springer, Berlin Heidelberg New York
28.
Marcucci G, Mrozek K, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA, Carroll AJ, Koduru PRK, Kolitz JE, Sterling LJ, Edwards CG, Anastasi J, Larson RA, Bloomfield CD (2004) Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol 22:2410–2418CrossRefPubMed
29.
Mauritzson N, Johansson B, Albin M, Billstrom R, Ahlgren T, Mikoczy Z, Nilsson PG, Hagmar L, Mitelman F (1999) A single-center population-based consecutive series of 1500 cytogenetically investigated adult hematological malignancies: karyotypic features in relation to morphology, age and gender. Eur J Haematol 62:95–102PubMedCrossRef
30.
Mehta AB, Bain BJ, Fitchett M, Shah S, Secker-Walker LM (1998) Trisomy 13 and myeloid malignancy—characteristic blast cell morphology: a United Kingdom cancer cytogenetics group survey. Br J Haematol 101:749–752CrossRefPubMed
31.
Mitelman F (1995) An international system for human cytogenetic nomenclature. Karger
32.
Moorman AV, Roman E, Willett EV, Dovey GJ, Cartwright RA, Morgan GJ (2001) Karyotype and age in acute myeloid leukemia. Are they linked? Cancer Genet Cytogenet 126(2):155–161CrossRefPubMed
33.
Mrozek K, Heinonen K, delaChapelle A, Bloomfield CD (1997) Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 24:17–31PubMed
34.
Olopade OI, Thangavelu M, Larson RA, Mick R, Kowalvern A, Schumacher HR, Lebeau MM, Vardiman JW, Rowley JD (1992) Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood 80:2873–2882PubMed
35.
Roumier C, Eclache V, Imbert M, Davi F, Macintyre E, Garand R, Talmant P, Lepelley P, Lai JL, Casasnovas O, Maynadie M, Mugneret F, Bilhou-Naberra C, Valensi F, Radford I, Mozziconacci MJ, Arnoulet C, Duchayne E, Dastugue N, Cornillet P, Daliphard S, Garnache F, Boudjerra N, Jouault H, Fenneteau O, Pedron B, Berger R, Flandrin G, Fenaux P, Preudhomme C (2003) M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d’Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 101:1277–1283CrossRefPubMed
36.
San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, Ramos F, Calmuntia MJ, Perez JJ, Gonzalez M, Orfao A (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98:1746–1751CrossRefPubMed
37.
Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T, Buchner T, Wormann B, Hiddemann W, Griesinger F (2000) Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 14:796–804CrossRefPubMed
38.
Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W (2003) New score predicting for prognosis in PML–RARA(+), AML1–ETO+, or CBFB-MYH11(+) acute myeloid leukemia based on quantification of fusion transcripts. Blood 102:2746–2755CrossRefPubMed
39.
Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T (2005) Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 43(3):227–238CrossRefPubMed
40.
Schoch C, Haferlach T, Bursch S, Kern W, Loeffler H, Hiddemann W (2000) Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 35(1):20–29CrossRef
41.
Schoch C, Haase D, Fonatsch C, Haferlach T, Loffler H, Schlegelberger B, Hossfeld DK, Becher R, Sauerland MC, Heinecke A, Wormann B, Buchner T, Hiddemann W (1997) The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. Br J Haematol 99:605–611CrossRefPubMed
42.
43.
Schoch C, Haferlach T, Haase D, Fonatsch C, Loffler H, Schlegelberger B, Staib P, Sauerland MC, Heinecke A, Buchner T, Hiddemann W (2001) Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 112:118–126CrossRefPubMed
44.
Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W, Haferlach T (2004) The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 89:1082–1090PubMed
45.
Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T (2003) AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 102:2395–2402CrossRefPubMed
46.
Swansbury GJ, Lawler SD, Alimena G, Arthur D, Berger R, Van den Berghe H, Bloomfield CD, de la Chappelle A, Dewald G, Garson OM et al (1994) Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 73(1):1–7CrossRefPubMed
47.
Venditti A, DelPoeta G, Buccisano F, Tamburini A, Cox MC, Stasi R, Bruno A, Aronica G, Maffei L, Suppo G, Simone MD, Forte L, Cordero V, Postorino M, Tufilli V, Isacchi G, Masi M, Papa G, Amadori S (1997) Minimally differentiated acute myeloid leukemia (AML-MO): comparison of 25 cases with other French–American–British subtypes. Blood 89:621–629PubMed
48.
Wolman SR, Gundacker H, Appelbaum FR, Slovak ML (2002) Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. Blood 100:29–35CrossRefPubMed
Metadata
Title
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients
Authors
Ulrike Bacher
Wolfgang Kern
Susanne Schnittger
Wolfgang Hiddemann
Claudia Schoch
Torsten Haferlach
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 12/2005
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-005-1099-0

Other articles of this Issue 12/2005

Annals of Hematology 12/2005 Go to the issue

Original Article

Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells

Original Article

Mutation analysis of the HFE gene associated with hereditary hemochromatosis in a Venezuelan sample

Original Article

Complement profile in childhood immune thrombocytopenic purpura: a prospective pilot study

Letter to the Editor

Occurrence of multiple myeloma 13 years after Hodgkin’s disease: chance or consequence?

Letter to the Editor

Successful treatment of refractory autoimmune thrombocytopenia with rituximab and cyclosporin A in a patient with chronic granulomatous disease

Original Article

Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma,results of a phase II single center study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits